V De Leo1, M C Musacchio, P Piomboni, A Di Sabatino, G Morgante. 1. University of Siena, Departement of Pediatrics, Obstetric and Reproduction, S. Maria alle Scotte Hospital, Bracci Street, 53100 Siena, Italy. deleo@unisi.it
Abstract
OBJECTIVES: To prospectively evaluate the safety of metformin administration during pregnancy in a group of PCOS patients by assessing its effect on the prevalence of gestational complications and neonatal outcome. STUDY DESIGN: Our prospective, single centre study included 98 pregnant women with PCOS treated with metformin throughout pregnancy and 110 normal pregnant controls. All PCOS patients were hyperinsulinemic and received metformin (1700-3000 mg/day) before conception and until 37 weeks' gestation. RESULTS: Metformin treatment in the pregnant PCOS patients resulted in significant decrease in miscarriage rate (9.1% vs 20%; p<0.05), gestational diabetes (0 vs 13%; p<0.005), and gestational hypertension (0 vs 11%; p<0.005) and a non-significant decrease in pre-eclampsia (0 vs 3%; p=.24), compared to the control group. Mean neonatal Apgar score, weight and length were comparable between the two groups. CONCLUSIONS: Continuing metformin therapy throughout pregnancy resulted in significant reduction in pregnancy complications with concomitant improved neonatal outcome, with no serious deleterious side effects.
OBJECTIVES: To prospectively evaluate the safety of metformin administration during pregnancy in a group of PCOSpatients by assessing its effect on the prevalence of gestational complications and neonatal outcome. STUDY DESIGN: Our prospective, single centre study included 98 pregnant women with PCOS treated with metformin throughout pregnancy and 110 normal pregnant controls. All PCOSpatients were hyperinsulinemic and received metformin (1700-3000 mg/day) before conception and until 37 weeks' gestation. RESULTS:Metformin treatment in the pregnant PCOSpatients resulted in significant decrease in miscarriage rate (9.1% vs 20%; p<0.05), gestational diabetes (0 vs 13%; p<0.005), and gestational hypertension (0 vs 11%; p<0.005) and a non-significant decrease in pre-eclampsia (0 vs 3%; p=.24), compared to the control group. Mean neonatal Apgar score, weight and length were comparable between the two groups. CONCLUSIONS: Continuing metformin therapy throughout pregnancy resulted in significant reduction in pregnancy complications with concomitant improved neonatal outcome, with no serious deleterious side effects.
Authors: C V Bishop; R L Stouffer; D L Takahashi; E C Mishler; M C Wilcox; O D Slayden; C A True Journal: Hum Reprod Date: 2018-04-01 Impact factor: 6.918
Authors: Harpal S Randeva; Bee K Tan; Martin O Weickert; Konstantinos Lois; John E Nestler; Naveed Sattar; Hendrik Lehnert Journal: Endocr Rev Date: 2012-07-24 Impact factor: 19.871
Authors: Cláudia de Oliveira Baraldi; Elaine C D Moisés; Teresa M de Jesus Ponte Carvalho; Natalícia de Jesus Antunes; Vera L Lanchote; Geraldo Duarte; Ricardo Carvalho Cavalli Journal: Clin Pharmacokinet Date: 2012-11 Impact factor: 6.447